Pharsight

Drugs that contain Gadopiclenol

1. Elucirem patents expiration

ELUCIREM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114863 GUERBET Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Sep, 2028

(4 years from now)

US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590246 GUERBET Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 21, 2027

NCE-1 date: 21 September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ELUCIREM family patents

Family Patents